Beta
Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists
medication Under reviewDual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists are a class of incretin-based compounds that activate both the GIP and GLP-1 receptors. The best-known agent in this class is tirzepatide, which is designed to enhance glucose-dependent insulin secretion, suppress glucagon when appropriate, slow gastric emptying, and reduce appetite. In healthy human physiology, GIP and GLP-1 both contribute to the regulation of post-meal insulin release, and combined signaling can produce additive insulinotropic effects. In clinical use, this class is primarily studied for metabolic outcomes, especially weight reduction, glucose control, and related cardiometabolic effects. Because these are prescription drugs rather than dietary supplements, standard retail cost is highly variable and typically much higher than a common over-the-counter supplement.
Research summary
The human evidence base for dual GIP/GLP-1 receptor agonism is strongest for metabolic outcomes. Healthy-human infusion studies show that combined incretin signaling can increase insulin secretion and improve glucose handling acutely, while clinical trials with tirzepatide in patient populations show substantial improvements in body weight and glycemic markers. Evidence in healthy subjects for non-metabolic benefits is limited, and most broader claims come from disease-state studies rather than studies in healthy people. Overall, the research consensus is that dual GIP/GLP-1 receptor agonists are potent metabolic drugs rather than general wellness supplements. In healthy human studies, the clearest documented effects are on appetite-related intake and acute insulin/glucose responses, while long-term benefits such as weight loss, improved lipids, and cardiometabolic risk reduction are better established in people with obesity or diabetes than in healthy volunteers.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists to your stack to report effects
Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Christensen M, Vedtofte L, Holst JJ, et al.
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
Holst JJ, Christensen M, Lund A, et al.
Effect of the Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide on Body Weight and Cardiometabolic Risk Factors in Adults With Obesity or Overweight
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
No reports yet
Be the first to report this effect and help the community.
Add Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists to your stack to report effects
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
Holst JJ, Christensen M, Lund A, et al.
Effect of the Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide on Body Weight and Cardiometabolic Risk Factors in Adults With Obesity or Overweight
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
No reports yet
Be the first to report this effect and help the community.
Add Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists to your stack to report effects
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
Holst JJ, Christensen M, Lund A, et al.
No reports yet
Be the first to report this effect and help the community.
Add Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists to your stack to report effects
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
Finan B, Capozzi ME, Campbell JE, et al.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Research (4 studies)
Effect of the Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide on Body Weight and Cardiometabolic Risk Factors in Adults With Obesity or Overweight
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
Holst JJ, Christensen M, Lund A, et al.
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
Finan B, Capozzi ME, Campbell JE, et al.
Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Christensen M, Vedtofte L, Holst JJ, et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!